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Autoimmune diseases (AIDs) are characterized by a multifactorial aetiology and a complex genetic background, with the MHC
region playing a major role. We genotyped for HLA-DRB1 locus 1228 patients with AIDs-213 with Systemic Lupus Erythematosus
(SLE), 166 with Psoriasis or Psoriatic Arthritis (Ps + PsA), 153 with Rheumatoid Arthritis (RA), 67 with Systemic Sclerosis (SSc),
536 with Multiple Sclerosis (MS), and 93 with Myasthenia Gravis (MG) and 282 unrelated controls. We confirmed previously
established associations of HLA-DRB1∗15 (OR = 2.17) and HLA-DRB1∗03 (OR = 1.81) alleles with MS, HLA-DRB1∗03 with SLE
(OR = 2.49), HLA-DRB1∗01 (OR = 1.79) and HLA-DRB1∗04 (OR = 2.81) with RA, HLA-DRB1∗07 with Ps + PsA (OR = 1.79), HLA-
DRB1∗01 (OR = 2.28) and HLA-DRB1∗08 (OR = 3.01) with SSc, and HLA-DRB1∗03 with MG (OR = 2.98). We further observed a
consistent negative association of HLA-DRB1∗13 allele with SLE, Ps + PsA, RA, and SSc (18.3%, 19.3%, 16.3%, and 11.9%, resp., versus
29.8% in controls). HLA-DRB1∗13 frequency in the AIDs group was 20.0% (OR = 0.58). Although different alleles were associated
with particular AIDs, the same allele, HLA-DRB1∗13, was underrepresented in all of the six diseases analysed. This observation
suggests that this allele may confer protection for AIDs, particularly for systemic and rheumatic disease. The protective effect of
HLA-DRB1∗13 could be explained by a more proficient antigen presentation by these molecules, favouring efficient clonal deletion
during thymic selection.
1. Introduction
Autoimmune diseases (AIDs) are chronic disorders origi-
nated by the loss of immunological tolerance to self-antigens.
This heterogeneous group of conditions present common
genetic risk factors and share several pathophysiological
mechanisms leading to overlapping clinical manifestations
targeting specific organs or multiple organ systems [1]. There
is evidence that they share similar immunogenetic mech-
anisms, even though they exhibit varying epidemiological
features and clinical manifestations [2, 3]. Underlying these
diverse clinical phenotypes is a deregulated immune system
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with an enriched ability to respond against self-tissues. The
fact that AIDs share several clinical signs and symptoms (i.e.,
subphenotypes) and also share physiopathological mecha-
nisms and genetic factors has been called autoimmune tau-
tology and indicates that theymay have a common origin [4].
The immune system is in charge of the defence against
external pathogens. For this purpose, T and B lymphocytes
are responsible for the immune response through regulated
cell-cell interactions and secretion of cytokines, chemokines,
and other inflammatory mediators. This defence against
external pathogens must occur without causing unnecessary
harm to self. To achieve this delicate balance, the majority of
self-reactiveT andB lymphocytes are destroyed in the thymus
and bone marrow through negative selection [5]. Neverthe-
less, this process is far from perfect, and self-reactive lym-
phocytes escape into the periphery. Consequently, peripheral
tolerance mechanisms are necessary to keep these self-
reactive cells in check [6]. Activated self-reactive T and B
cells promote autoimmunity when the effector and regulatory
balance of the immune response is disturbed [7].
Major histocompatibility complex (MHC) molecules are
widely distributed surface membrane glycoproteins that
present antigenic peptides to T cell receptors (TCRs). Devel-
oping thymocytes encounter a highly heterogeneous reper-
toire of self (endogenous) peptide-MHC (pMHC) complexes
on thymic epithelial cells, the main thymus antigen present-
ing cells. The affinity/avidity with which these thymocyte
TCRs bind self pMHC determines if it is destined to perish
or if it will survive [8]. In this way, a repertoire of peripheral
T cells that is essentially self-tolerant is generated [6, 9, 10].
Several hypotheses have been put forward to explain how
MHC polymorphisms influence autoimmunity risk or pro-
tection.They must do so, somehow, by shaping the central or
peripheral T cell repertoires toward autoimmune resistance
or proclivity [8]. A protective MHC profile could achieve
this by the selection of a T cell repertoire with diminished
pathogenicity [11]. On the other hand, protective MHC
molecules may keep autoimmunity in check by favouring the
negative selection of particular self-reactive T cells [12–14].
The functional basis of the association between specific
HLA alleles and development of AIDs can be classically
explained by two possible etiopathogenic models [15].
The molecular mimicry hypothesis proposes that certain
HLA alleles are more efficient in presenting pathogen epi-
topes that share structural features with self-peptides to
mature T cells. Once the response to the pathogen is initiated
the self-antigen is also recognized and disease ensues.
Central selection failure proposes that certain HLA alleles
are less efficient at presenting self-peptides to developing T
cells in the thymus, so negative selection fails.
A different hypothesis proposes that different alleles can
modulate the immunologic profile of an individual, through
antigen-independent mechanisms, resulting in either pro-
moting a higher autoimmune predisposition or, in oppo-
sition, a more efficient immune regulation. Given the
consistent association of HLA-DRB1 alleles with different
autoimmune diseases (Table 1), we explored the idea that
the same HLA-DRB1 alleles could be influencing several
different autoimmune diseases. To this end we compared the
immunogenetic profile in different AIDs.This study includes
four autoimmune systemic diseases, namely, Systemic Lupus
Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis
or Psoriatic Arthritis (Ps + PsA), and Systemic Sclerosis (SSc).
Patients with Multiple Sclerosis (MS) and Myasthenia Gravis
(MG) were also included.
2. Patients and Methods
2.1. Patients and Controls. A total of 1228 patients with AIDs,
213 patients with SLE and 153 patients with RA diagnosed
according to the American College of Rheumatology (ACR)
criteria, 166 patients with Ps + PsA, 67 with SSc, 536 with
definitive diagnosis ofMS according to the revisedMcDonald
criteria, and 93 with MG, were recruited from the Neurology
and Medicine Outpatient Clinic of Centro Hospitalar do
Porto-Hospital de Santo Anto´nio (CHP-HSA). The HLA-
DRB1 frequencies of patients were compared with the ones
of a control group consisting of 282 unrelated individuals
without disease and from the same geographic origin (north
of Portugal).
2.2. HLA-DRB1 Genotyping. Peripheral blood samples
(10mL)were collected inEDTA.GenomicDNAwas obtained
from proteinase-K–treated peripheral blood leukocytes by
using a Salting-Out procedure [27]. Low-resolution genotyp-
ing for HLA–DRB1 locus (i.e., 2-digit HLA nomenclature)
was performed using polymerase chain reaction and
sequence-specific primers (PCR-SSP), based on methods
previously described [28]. In order to produce PCR-SSP reac-
tions able to detect and discriminate each of the knownHLA-
DRB1 genes, primers were designed using sequence align-
ments comprising all HLA-DRB1 variants and were validated
by the Twelfth International Histocompatibility Workshop.
PCR products were visualized under ultraviolet light after
running in a 1.5% agarose gel containing ethidium bromide.
2.3. Statistical Analysis. To identify the HLA-DRB1 genes
contributing to the six different AIDs, we applied stepwise
logistic regression on an allelic level, using forward selection
which involves startingwith no variables in themodel, testing
the addition of each variable using a chosen model com-
parison criterion, adding the variable (if any) that improves
the model the most, and repeating this process until none
improves themodel. It should be noted that odds ratios (ORs)
obtained in a multivariable logistic regression analysis are
adjusted for all the other genes included in the model and
therefore differ from those obtained when a given gene is
compared with all other genes. The data were analysed using
IBM SPSS 20 statistical software.
3. Results
A total of 1228 cases and 282 controls were analysed and
different types of association between alleles and AIDs were
found (Table 2). These included three risk alleles for two or
more AIDs, two protective alleles for two or more AIDs, and
three risk alleles for a particular AID.
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Table 1: HLA-DRB1 alleles associated with SLE, Ps + PsA, RA, SSc, MS, and MG.
Autoimmune disease HLA-DRB1 associated allele References
Susceptibility Protection
Systemic Lupus
Erythematosus (SLE)
HLA-DRB1∗03
HLA-DRB1∗08
HLA-DRB1∗15
HLA-DRB1∗09
HLA-DRB1∗13 [16–18]
Psoriasis or Psoriatic Arthritis
(Ps + PsA) HLA-DRB1
∗07 — [19, 20]
Rheumatoid Arthritis (RA)
HLA-DRB1∗01
HLA-DRB1∗04
HLA-DRB1∗10
HLA-DRB1∗13 [21]
Systemic Sclerosis (SSc)
HLA-DRB1∗01
HLA-DRB1∗08
HLA-DRB1∗11
HLA-DRB1∗07
HLA-DRB1∗15 [22, 23]
Multiple Sclerosis (MS)
HLA-DRB1∗03
HLA-DRB1∗08
HLA-DRB1∗15
HLA-DRB1∗10
HLA-DRB1∗14 [24, 25]
Myasthenia Gravis (MG) HLA-DRB1∗03 — [26]
Table 2: Associations between HLA class II and six AIDs: SLE, Ps + PsA, RA, SSc, MS, and MG.
Controls
(𝑛 = 282)
SLE
(𝑛 = 213)
Ps + PsA
(𝑛 = 166)
RA
(𝑛 = 153)
SSc
(𝑛 = 67)
MS
(𝑛 = 536)
MG
(𝑛 = 93)
Total
(𝑛 = 1228)
HLA-DRB1∗01 66 (23.4%) 40 (18.8%) 39 (23.5%)
50 (32.7%)
OR = 1.79
p = 0.017
28 (41.8%)
OR = 2.28
p = 0.006
100 (18.7%) 23 (24.7%) 280 (22.8%)
HLA-DRB1∗03 44 (15.6%)
73 (34.3%)
OR = 2.49
p = 4.2 × 10−5
25 (15.1%) 28 (18.3%) 11 (16.4%)
123 (22.9%)
OR = 1.81
p = 0.003
33 (35.5%)
OR = 2.98
p = 6.1 × 10−5
293 (23.9%)
OR = 1.51
p = 0.022
HLA-DRB1∗04 69 (24.5%) 42 (19.7%) 46 (27.7%)
73 (47.7%)
OR = 2.81
p = 6 × 10−6
13 (19.4%) 128 (23.9%) 23 (24.7%) 325 (26.5%)
HLA-DRB1∗07 72 (25.5%) 55 (25.8%)
66 (39.8%)
OR = 1.79
p = 0.006
38 (24.8%) 14 (20.9%) 147 (27.4%) 23 (24.7%) 343 (27.9%)
HLA-DRB1∗08 24 (8.5%) 21 (10.0%) 10 (6.0%)
3 (2.0%)
OR = 0.24
p = 0.026
15 (22.4%)
OR = 3.01
p = 0.004
65 (12.1%)
OR = 1.73
p = 0.033
7 (7.5%) 121 (9.9%)
HLA-DRB1∗09 14 (5.0%)
2 (1.0%)
OR = 0.18
p = 0.027
5 (3.0%)
0 (0.0%)∗
OR = 0.95
p = 0.003
3 (4.5%)
5 (1.0%)
OR = 0.22
p = 0.004
2 (2.2%)
17 (1.4%)
OR = 0.23
p = 1 × 10−4
HLA-DRB1∗13 84 (29.8%)
39 (18.3%)
OR = 0.58
p = 0.016
32 (19.3%)
OR = 0.62
p = 0.050
25 (16.3%)
OR = 0.58
p = 0.044
8 (11.9%)
OR = 0.42
p = 0.035
124 (23.1%) 17 (18.3%)
245 (20.0%)
OR = 0.58
p = 0.004
HLA-DRB1∗15 56 (19.9%) 55 (25.8%) 22 (13.3%) 17 (11.1%) 12 (17.9%)
175 (32.7%)
OR = 2.17
p = 2 × 10−5
15 (16.1%) 296 (24.1%)
AIDs: autoimmune diseases; SLE: Systemic Lupus Erythematosus; Ps + PsA: Psoriasis or Psoriatic Arthritis; RA: Rheumatoid Arthritis; SSc: Systemic Sclerosis;
MS: Multiple Sclerosis; MG: Myasthenia Gravis. ∗Fisher’s exact test was used to calculate this value.
HLA-DRB1∗13 was a protective allele for four AIDs: SLE
(18.3% versus 29.8%, 𝑝 = 0.016, OR = 0.58, and 95% CI =
0.37–0.90), Ps + PsA (19.3% versus 29.8%, 𝑝 = 0.050, OR =
0.621, and 95% CI = 0.39–1.00), RA (16.3% versus 29.8%, 𝑝 =
0.044, OR = 0.58, and 95% CI = 0.34–0.98), and SSc (11.9%
versus 29.8%, 𝑝 = 0.035, OR = 0.42, and 95%CI = 0.19–0.94).
There was a specific risk allele associated with three AIDs.
HLA-DRB1∗03 was found to be a risk factor for SLE (34.3%
versus 15.6%, 𝑝 = 4.2 × 10−5, OR = 2.49, and 95% CI =
1.61–3.86), MS (22.9% versus 15.6%, 𝑝 = 0.003, OR = 1.81,
and 95% CI = 1.23–2.67), and MG (35.5% versus 15.6%, 𝑝 =
6.1 × 10
−5, OR = 2.98, and 95% CI = 1.75–5.07). There were
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two risk alleles associatedwith twoAIDs:HLA-DRB1∗08was
positively associated with MS (12.1% versus 8.5%, 𝑝 = 0.033,
OR = 1.73, and 95% CI = 1.05–2.87) and SSc (22.4% versus
8.5%, 𝑝 = 0.004, OR = 3.01, and 95% CI = 1.43–6.31) and
HLA-DRB1∗01 was found to be a risk factor for RA (32.7%
versus 23.4%, 𝑝 = 0.017, OR = 1.79, and 95% CI = 1.11–2.88)
and SSc (41.8% versus 23.4%, 𝑝 = 0.006, OR = 2.28, and 95%
CI = 1.27–4.09).
HLA-DRB1∗09 was negatively associated with SLE (1.0%
versus 5.0%, 𝑝 = 0.027, OR = 0.18, and 95% CI = 0.04–0.83),
MS (1.0% versus 5.0%, 𝑝 = 0.004, OR = 0.22, and 95% CI =
0.08–0.63), and RA (0.0% versus 1.0%, 𝑝 = 0.003, OR = 0.95,
and 95% CI = 0.93–0.98).
Three risk disease-specific alleles were found: HLA-
DRB1∗04 for RA (47.7% versus 24.5%,𝑝 = 6×10−6, OR= 2.81,
and 95% CI = 1.79–4.39), HLA-DRB1∗07 for Ps + PsA (39.8%
versus 25.5%, 𝑝 = 0.006, OR = 1.79, and 95% CI = 1.18–2.72),
and HLA-DRB1∗15 forMS (32.7% versus 19.9%, 𝑝 = 2×10−5,
OR = 2.17, and 95% CI = 1.53–3.10).
Considering AIDs as a group, HLA-DRB1∗03 frequency
was significantly higher (23.9% versus 15.6%, 𝑝 = 0.022,
OR = 1.51, and 95% CI = 1.0–2.15) compared with controls;
conversely HLA-DRB1∗13 (20.0% versus 29.8%, 𝑝 = 0.004,
OR = 0.58, and 95% CI = 0.43–0.79) and HLA-DRB1∗09
(1.4% versus 5.0%, 𝑝 = 1 × 10−4, OR = 0.23, and 95% CI =
0.11–0.49) frequencies were significantly lower.
4. Discussion
Through a systematic review of published works, Cruz-Tapias
and collaborators, in 2012, identified some common HLA
class II alleles that contribute to susceptibility to AIDs in
Latin Americans [3]. The present study is, to date and to
the best of our knowledge, the only one that addresses the
hypothesis that a HLA-DRB1 allele could influence different
autoimmune diseases, using a new cohort, encompassing six
different autoimmune diseases.
In this study we observed associations of different HLA-
DRB1 alleles with several AIDs. We confirmed positive and
negative associations inMS [24, 25], SLE [16–18], Ps +PsA [19,
20], RA [21], SSc [22, 23], and MG [26], previously reported
in our or other populations.
When AIDs studied were considered as a group, HLA-
DRB1∗03 allele was significantly overrepresented, as already
described [29]. It has been shown that this allele has low
affinity for CLIP (class II-associated invariant chain peptide)
and may not require HLA-DM to ensure peptide presen-
tation, preventing efficient peptide selection and allowing
the binding of low stability peptides [30]. Concerning the
observed negative association with HLA-DRB1∗09, we think
that this is likely a spurious association, as this is a rare allele
and the frequency found in controls is, for some reason,
double the one reported for the Portuguese population [31].
Our observations suggest that the presence of HLA-
DRB1∗13 allele may confer protection for AIDs. HLA-
DRB1∗13 is a high frequency allele in the general population
both in Portugal [31] andworldwide. Our results confirm that
the lower frequency of HLA-DRB1∗13 in every individual
AIDs group is not secondary to the deviations granted by
the concurrent positive associations.When the data obtained
from previous studies are taken into consideration, the HLA-
DRB1∗13 allele seems to be a universal protective allele for
RA. It was reported as protective against RA in Asian [32,
33], Turkish [34], and several European populations [35–37].
Recently this allele was also described to be protective in
SLE in the Japanese population [18] and forANCA-associated
vasculitis in the Dutch population [38].
Subtle structural differences in the HLA molecule have
functional implications at the protein level. Specific amino
acid patterns at the peptide binding cleft are involved in dis-
ease susceptibility, such as thewell-known shared epitope first
described in the RA susceptibility alleles HLA-DRB1∗01 and
HLA-DRB1∗04 [37, 39]. Similar to the shared epitope classi-
fication of susceptibility alleles, protective HLA-DRB1 alleles
have been categorized according to several models. One of
the most accepted classifications proposes that protection
against RA is conferred by the DERAA sequence at positions
70–74 of the HLA-DRB1 allele [40]. Other models suggest
that protection is conferred by an aspartic acid at position
70 (D70 allele) [41] or an isoleucine at position 67 (I67
allele) of the HLA-DRB1 molecule. Because it was unclear
which HLA-DRB1 alleles were protective a meta-analysis
was performed involving four European populations with
>2,700 patients and >3,000 control subjects. The objective
was to investigate exhaustively which HLA-DRB1 alleles were
associated with protection against RA [36]. Interestingly,
this study showed that the protective effect attributed to
DERAA and D70 was no longer present after the exclusion
of HLA-DRB1∗13. The authors concluded that this evidence
indicates that HLA-DRB1∗13 rather than DERAA, D70, or
I67 is associated with protection [36]. In a recent study
van Heemst and collaborators identify citrullinated vinculin,
present in the joints of ACPA+ RA patients, as an autoantigen
targeted by ACPA and CD4+ T cells. These T cells recognize
an epitope with the core sequence DERAA, which is also
found in many microbes and in protective HLA-DRB1∗13
molecules, presented by predisposing HLA-DQ molecules.
Intriguingly, DERAA-directed T cells were not detected in
HLA-DRB1∗13+ donors, indicating that the DERAA epitope
fromHLA-DRB1∗13 could mediate thymic tolerance in these
donors and explain the protective effects associated with
HLA-DRB1∗13. They suggest that subjects born with HLA-
DRB1∗13 will present the HLA-DRB1∗13-derived DERAA-
peptide in the thymus, leading to tolerization of the DERAA-
reactive T cell response [42]. The negative association we
describe here supports the idea that the HLA-DRB1∗13
allele, possibly by its specific structural features, may as well
confer resistance to several other AIDs. The protective effect
of HLA-DRB1∗13 could be explained by a more proficient
antigen presentation by these molecules [43, 44], favouring
an efficient thymic selection. As a result, negative selection
anddevelopment ofDR-driven autoreactive regulatoryT cells
are promoted [8].
A different model would relate HLA molecules with the
presence of specific endophenotypes indirectly associated
with autoimmunity. Other studies of our group suggest
that the HLA genotype may primarily influence the general
activation state of CD4 T cells [45]. The protective effect
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of HLA-DRB1∗13 could also be explained by this effect.
Curiously, several reports have suggested an association
of HLA-DRB1∗13 and/or HLA-DQB1∗06 with slow dis-
ease progression in human immunodeficiency virus (HIV)
infected individuals, meaning that among HIV controllers
there is an association between the presence of certain class
II HLA alleles and strong CD4 T cell responses [46, 47].
Although different alleles are associated with particular
AIDs, the same allele, HLA-DRB1∗13, was underrepresented
in all six diseases. This difference is statistically significant
for the four rheumatic diseases studied. This observation
suggests that this allele confers protection to AIDs in general
and particularly to rheumatic diseases.
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